×

medication

Read More

The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue

The search continues.

Alzheimer
Read More

The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle?

Statistician Hong Liu-Seifert will emerge from The Cave knowing the outlook for a $90 billion company—what high-level executives are calling a “binary” event that could result in bringing a drug to market by 2018, and windfall profits; or another blow to the field of Alzheimer’s research.

Read More

Life after Zyprexa: the Future of Eli Lilly and Company

“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”

Zyprexa
Read More

Side Effects

With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.

X
X